Tower Research Capital LLC TRC Acquires 1,396 Shares of Amedisys, Inc. (NASDAQ:AMED)

Tower Research Capital LLC TRC raised its holdings in shares of Amedisys, Inc. (NASDAQ:AMED) by 66.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,512 shares of the health services provider’s stock after acquiring an additional 1,396 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Amedisys were worth $319,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of Amedisys by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 3,216,120 shares of the health services provider’s stock worth $291,992,000 after acquiring an additional 10,817 shares in the last quarter. Norges Bank acquired a new stake in shares of Amedisys in the 4th quarter valued at approximately $83,061,000. Alpine Associates Management Inc. boosted its holdings in shares of Amedisys by 3.2% in the 4th quarter. Alpine Associates Management Inc. now owns 888,120 shares of the health services provider’s stock valued at $80,632,000 after buying an additional 27,403 shares during the last quarter. Wealthfront Advisers LLC acquired a new stake in shares of Amedisys in the 4th quarter valued at approximately $72,970,000. Finally, Alliancebernstein L.P. boosted its holdings in shares of Amedisys by 2.0% in the 4th quarter. Alliancebernstein L.P. now owns 677,787 shares of the health services provider’s stock valued at $61,536,000 after buying an additional 13,587 shares during the last quarter. 94.36% of the stock is owned by institutional investors.

Amedisys Trading Up 0.3 %

Shares of Amedisys stock opened at $95.20 on Friday. The business has a fifty day simple moving average of $92.49 and a two-hundred day simple moving average of $91.77. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $98.95. The company has a market capitalization of $3.12 billion, a price-to-earnings ratio of 37.78, a P/E/G ratio of 1.78 and a beta of 0.89. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.12. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business had revenue of $594.78 million during the quarter, compared to the consensus estimate of $597.43 million. During the same quarter last year, the firm posted $1.03 EPS. The company’s quarterly revenue was up 4.1% on a year-over-year basis. Research analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on AMED shares. Stephens reissued an “equal weight” rating and issued a $101.00 price objective on shares of Amedisys in a report on Tuesday, March 4th. Royal Bank of Canada reissued an “outperform” rating and issued a $100.00 price objective on shares of Amedisys in a report on Wednesday, April 16th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $100.75.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.